At a glance
ClinicalIndex Comparison Record- ✓Biopsy-proven pancreatic adenocarcinoma (locally advanced, metastatic, or resectable)
- ✓Group A: Responding (stable disease or tumor reduction) after 3 cycles of first-line chemotherapy
- ✓Group B: Failed first-line chemo or intolerant/ineligible/unwilling for standard therapy
- ✓Group C: Resectable cancer completed neo-adjuvant chemo/radiotherapy/combination
- ✕Severe intercurrent infection
- ✕Active HIV infection or HIV positive
- ✕Receiving systemic corticosteroids (eligible if off ≥48 hours)
- ✕Pregnant women
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tumor-Associated Antigen (TAA) Specific Cytotoxic T Lymphocytes Administered in Patients With Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating multiTAA specific T cells for Pancreatic Cancer. Completed, enrolled 37 participants across 3 sites.
Detailed Summary
Status - CLOSED TO PATIENT ENROLLMENT (CNPE) Patients who have pancreatic cancer that has come back or has not gone away after treatment, including the standard treatment for this disease or patients who are not eligible for or have elected not to receive standard of care chemotherapy, and patients who will have surgery after treatment for pancreatic cancer are eligible for this study. This is a research study using special immune system cells called tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes, a new experimental therapy. The proteins that are targeted in this study are called tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They do not show, or they show up in low quantities, on normal human cells. In this study, five common TAAs will be targeted. They are called NY-ESO-1, MAGEA4, PRAME, Survivin and SSX2. On a different study, patients have been treated and so far this treatment has shown to be safe. Investigators now want to try this treatment in patients with pancreatic cancer. These TAA-specific cytotoxic T lymphocytes (TAA-CTLs) are an investigational product not approved by the Food and Drug Administration. \*Arm A and Arm B are closed to new patient enrollment.\*
Study Details
Timeline
Interventions
Each patient will receive 6 infusions of multiTAA T cells at a fixed cell dose (1 x 10\^7 cells/m2) at the times specified in the group description. The expected volume of infusion will be 1 to 10 cc.